News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
547,695 Results
Type
Article (46295)
Company Profile (124)
Press Release (501269)
Multimedia
Podcasts (131)
Webinars (19)
Section
Business (145805)
Career Advice (2416)
Deals (28080)
Drug Delivery (134)
Drug Development (68545)
Employer Resources (156)
FDA (15907)
Job Trends (12051)
News (265542)
Policy (29886)
Tag
Academia (2312)
Academic (1)
Accelerated approval (24)
Adcomms (35)
Allergies (121)
Alliances (36276)
ALS (146)
Alzheimer's disease (1660)
Antibody-drug conjugate (ADC) (262)
Approvals (15957)
Artificial intelligence (439)
Autoimmune disease (114)
Automation (26)
Bankruptcy (312)
Best Places to Work (9201)
BIOSECURE Act (23)
Biosimilars (171)
Biotechnology (72)
Bladder cancer (140)
Brain cancer (49)
Breast cancer (494)
Cancer (3952)
Cardiovascular disease (363)
Career advice (2040)
Career pathing (38)
CAR-T (228)
CDC (59)
Cell therapy (634)
Cervical cancer (32)
Clinical research (58093)
Collaboration (1245)
Company closure (4)
Compensation (1004)
Complete response letters (63)
COVID-19 (2698)
CRISPR (81)
C-suite (614)
Cystic fibrosis (133)
Data (4986)
Decentralized trials (2)
Denatured (30)
Depression (119)
Diabetes (432)
Diagnostics (5460)
Digital health (31)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (189)
Drug pricing (199)
Drug shortages (33)
Duchenne muscular dystrophy (210)
Earnings (61875)
Editorial (59)
Employer branding (20)
Employer resources (141)
Events (81139)
Executive appointments (859)
FDA (18524)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (17)
Funding (1128)
Gene editing (178)
Generative AI (38)
Gene therapy (536)
GLP-1 (998)
Government (4157)
Grass and pollen (8)
Guidances (368)
Healthcare (14881)
HIV (48)
Huntington's disease (43)
IgA nephropathy (77)
Immunology and inflammation (257)
Immuno-oncology (27)
Indications (62)
Infectious disease (2930)
Inflammatory bowel disease (172)
Inflation Reduction Act (13)
Influenza (93)
Intellectual property (195)
Interviews (453)
IPO (14110)
IRA (56)
Job creations (3170)
Job search strategy (1672)
Kidney cancer (16)
Labor market (75)
Layoffs (608)
Leadership (37)
Legal (7012)
Liver cancer (85)
Longevity (11)
Lung cancer (553)
Lymphoma (293)
Machine learning (34)
Management (52)
Manufacturing (600)
MASH (155)
Medical device (11497)
Medtech (11526)
Mergers & acquisitions (14851)
Metabolic disorders (1159)
Multiple sclerosis (129)
NASH (22)
Neurodegenerative disease (274)
Neuropsychiatric disorders (74)
Neuroscience (2690)
NextGen: Class of 2025 (4997)
Non-profit (3187)
Now hiring (26)
Obesity (568)
Opinion (266)
Ovarian cancer (131)
Pain (158)
Pancreatic cancer (175)
Parkinson's disease (239)
Partnered (24)
Patents (416)
Patient recruitment (337)
Peanut (51)
People (43878)
Pharmaceutical (33)
Pharmacy benefit managers (29)
Phase I (17421)
Phase II (25149)
Phase III (20606)
Pipeline (3368)
Policy (309)
Postmarket research (2208)
Preclinical (7142)
Press Release (31)
Prostate cancer (213)
Psychedelics (49)
Radiopharmaceuticals (225)
Rare diseases (715)
Real estate (4299)
Recruiting (64)
Regulatory (22525)
Reports (38)
Research institute (2101)
Resumes & cover letters (403)
Rett syndrome (21)
RNA editing (12)
RSV (70)
Schizophrenia (136)
Series A (190)
Series B (151)
Service/supplier (9)
Sickle cell disease (84)
Special edition (24)
Spinal muscular atrophy (136)
Sponsored (43)
Startups (2783)
State (1)
Stomach cancer (19)
Supply chain (96)
Tariffs (97)
The Weekly (100)
Vaccines (1030)
Venture capital (75)
Weight loss (408)
Women's health (56)
Worklife (21)
Date
Last 7 days (519)
Last 30 days (2259)
Last 365 days (28476)
2025 (27050)
2024 (31447)
2023 (35036)
2022 (45111)
2021 (48538)
2020 (45562)
2019 (36243)
2018 (27424)
2017 (27840)
2016 (25833)
2015 (28007)
2014 (21815)
2013 (17835)
2012 (18995)
2011 (19432)
2010 (17561)
Location
Africa (684)
Alabama (60)
Alaska (6)
Arizona (210)
Arkansas (10)
Asia (32111)
Australia (5620)
California (9386)
Canada (2322)
China (779)
Colorado (368)
Connecticut (425)
Delaware (269)
Europe (78443)
Florida (1421)
Georgia (289)
Hawaii (3)
Idaho (39)
Illinois (650)
India (44)
Indiana (391)
Iowa (20)
Japan (327)
Kansas (101)
Kentucky (24)
Louisiana (18)
Maine (71)
Maryland (1211)
Massachusetts (6862)
Michigan (247)
Minnesota (502)
Mississippi (5)
Missouri (107)
Montana (12)
Nebraska (20)
Nevada (103)
New Hampshire (59)
New Jersey (2583)
New Mexico (14)
New York (2462)
North Carolina (1244)
North Dakota (8)
Northern California (4541)
Ohio (245)
Oklahoma (14)
Oregon (31)
Pennsylvania (1849)
Puerto Rico (13)
Rhode Island (29)
South America (1041)
South Carolina (56)
South Dakota (1)
Southern California (3640)
Tennessee (139)
Texas (1375)
United States (33175)
Utah (243)
Virginia (219)
Washington D.C. (71)
Washington State (748)
West Virginia (4)
Wisconsin (88)
Wyoming (1)
547,695 Results for "transgene s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
October 13, 2025
·
6 min read
Press Releases
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
October 20, 2025
·
9 min read
Press Releases
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025
July 28, 2025
·
6 min read
Press Releases
Verinomics Introduces Transgene-Free Gene Editing and Genomic-Driven Accelerated Breeding Platforms for Specialty Crops
March 10, 2025
·
4 min read
Transgene’s Combined General Meeting of May 5, 2023
The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held at 9:00 a.m. at the Company’s headquarters.
May 5, 2023
·
4 min read
Press Releases
Kraig Biocraft Laboratories Announces the Launch of Advanced Gene-Splicing Program and New Transgenics
April 16, 2025
·
3 min read
Alzheimer’s disease
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s
Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or “perceived” overhang on Biogen and the anti-amyloid antibody class in general, clearing the way for increased uptake of Leqembi and Eli Lilly’s Kisunla.
November 24, 2025
·
3 min read
·
Heather McKenzie
Podcast
Prasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs, Next-Gen Obesity Drugs
Experts unpack the implications of CBER Director Vinay Prasad’s claim that COVID vaccines have caused 10+ child deaths; the 2025 Clinical Trials on Alzheimer’s Disease conference continues following two disappointing readouts; and Novo Nordisk’s amycretin yields promising weight loss results.
December 3, 2025
·
1 min read
·
Heather McKenzie
Huntington’s disease
FDA Minutes Confirm Challenging Path Ahead for UniQure’s Huntington’s Gene Therapy
Investor optimism has waned as final minutes from uniQure’s pre-BLA meeting with the FDA convey that data from the company’s Phase I/II studies of AMT-130 are “unlikely” to provide the primary evidence to support a biologics license application.
December 4, 2025
·
2 min read
·
Heather McKenzie
Alzheimer’s disease
Novo’s GLP-1 Fails to Slow Alzheimer’s, Sending Shares Down 10%
“We felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,” Martin Holst Lange, Novo’s R&D chief, said on Monday.
November 24, 2025
·
2 min read
·
Annalee Armstrong
1 of 54,770
Next
